

Applicants: Keith et al.
U.S.S.N. 09/920,532

4 ~~8~~. (Original) The method of claim 1, wherein the interleukin-11 is administered daily until improvement of the disorder is observed.

5 ~~8~~. (Original) The method of claim 1, wherein the interleukin-11 is administered daily until remission of the disorder is observed.

6 ~~8~~. (Original) The method of claim 1, wherein the gastrointestinal disorder is gastroesophageal reflux disease.

7 ~~8~~. (Original) The method of claim 1, wherein the gastrointestinal motility disorder is post-operative adynamic ileus.

8 ~~8~~. (Original) The method of claim 1, wherein said subject is a preterm infant and said gastrointestinal disorder is intolerance to oral feeding.

8. (Original) A method of preventing the onset of a gastrointestinal disorder in a mammal which comprises administering to the mammal a therapeutically effective amount of interleukin-11, wherein said gastrointestinal disorder is selected from the group consisting of gastroesophageal reflux disease, post-operative adynamic ileus and intolerance to oral feeding.

Applicants: Keith et al.
U.S.S.N. 09/920,532

9. (Original) The method of claim 8, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 1000 μg /kg body weight.

Claims 10-13 (Cancelled)

³
Claim ~~14~~ (New) The method of claim 1, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg /kg body weight.

Claim 15 (New) The method of claim ~~8~~, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg /kg body weight.